Joyoti Dey
YOU?
Author Swipe
View article: Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors Open
KT-333is a first-in-class, potent, highly selective, heterobifunctional degrader of the signal transducer and activator of transcription 3 (STAT3) protein. Aberrant activation of STAT3 due to genetic aberrations or deregulated cytokine sig…
View article: A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia Open
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that continues to have poor prognosis despite recent therapeutic advances. Venetoclax (Ven), a BCL2-inhibitor has shown a high response rate in AML; however, relapse is i…
View article: Supplemental Figure 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Clinical Trial Design
View article: Supplemental Figure 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Representative images of tumors from patients who received radiation treatment.
View article: Data from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Data from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Purpose:A persistent issue in cancer drug development is the discordance between robust antitumor drug activity observed in laboratory models and the limited benefit frequently observed when patients are treated with the same agents in cli…
View article: Supplemental Table 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Device performance
View article: Supplemental Table 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
All adverse events reported on the study
View article: Supplemental Figure 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Distinct drug induced phenotypes and apoptotic responses specific to drug mechanism of action are seen at sites of CIVO microinjection.
View article: Data from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Data from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Purpose:A persistent issue in cancer drug development is the discordance between robust antitumor drug activity observed in laboratory models and the limited benefit frequently observed when patients are treated with the same agents in cli…
View article: Supplemental Figure 5 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 5 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Microinjection of olaratumab does not inhibit PDGFRα, ERK, or S6 phosphorylation.
View article: Supplemental Figure 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Clinical Trial Design
View article: Supplemental Table 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
All adverse events reported on the study
View article: Supplemental Figure 4 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 4 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Increased phosphorylation of PDGFR� and downstream effectors in an undifferentiated pleomorphic sarcoma displaying a lack of apoptotic response to microdosed doxorubicin.
View article: Supplementary Legend from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplementary Legend from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Supplementary Legend
View article: Supplemental Table 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Table of microinjected drugs
View article: Supplemental Table 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Device performance
View article: Supplemental Figure 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Representative images of tumors from patients who received radiation treatment.
View article: Supplementary Legend from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplementary Legend from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Supplementary Legend
View article: Supplemental Figure 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Distinct drug induced phenotypes and apoptotic responses specific to drug mechanism of action are seen at sites of CIVO microinjection.
View article: Supplemental Table 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Table 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Table of microinjected drugs
View article: Supplemental Figure 4 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 4 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Increased phosphorylation of PDGFR� and downstream effectors in an undifferentiated pleomorphic sarcoma displaying a lack of apoptotic response to microdosed doxorubicin.
View article: Supplemental Figure 5 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Supplemental Figure 5 from Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma Open
Microinjection of olaratumab does not inhibit PDGFRα, ERK, or S6 phosphorylation.
View article: Supplementary Figure 4 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Figure 4 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 12536K, MyoD expression is higher in the tumor periphery compared to the inner core.
View article: Supplementary Methods and Figure Legend from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Methods and Figure Legend from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 112K, Supplementary Figure legends, primer sequences and Western blot antibody details.
View article: Supplementary Figure 4 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Figure 4 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 12536K, MyoD expression is higher in the tumor periphery compared to the inner core.
View article: Supplementary Methods and Figure Legend from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Methods and Figure Legend from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 112K, Supplementary Figure legends, primer sequences and Western blot antibody details.
View article: Supplementary Figure 5 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Figure 5 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 4148K, Loss of MyoD does not influence its canonical targets in the myogenic differentiation program.
View article: Supplementary Figure 3 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Supplementary Figure 3 from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
PDF file - 1235K, MyoD is expressed in proliferating tumor cells in SmoA1, SmoA2 and Ptch conditional knock out medulloblastoma mouse models.
View article: Data from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Data from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
While medulloblastoma, a pediatric tumor of the cerebellum, is characterized by aberrations in developmental pathways, the majority of genetic determinants remain unknown. An unbiased Sleeping Beauty transposon screen revealed MyoD as a pu…
View article: Data from MyoD Is a Tumor Suppressor Gene in Medulloblastoma
Data from MyoD Is a Tumor Suppressor Gene in Medulloblastoma Open
While medulloblastoma, a pediatric tumor of the cerebellum, is characterized by aberrations in developmental pathways, the majority of genetic determinants remain unknown. An unbiased Sleeping Beauty transposon screen revealed MyoD as a pu…